Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 28, 2016

Primary Completion Date

February 14, 2022

Study Completion Date

March 31, 2024

Conditions
Glioma
Interventions
DRUG

LBH589

"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

20892

National Cancer Institute, Bethesda

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine, Houston

90026

Children's Hospital Los Angeles, Los Angeles

94304

Stanford University and Lucile Packard Children's Hospital, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Pediatric Brain Tumor Consortium

NETWORK

NCT02717455 - Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Biotech Hunter | Biotech Hunter